MX2011012140A - Ranolazina para el tratamiento de problemas del snc. - Google Patents
Ranolazina para el tratamiento de problemas del snc.Info
- Publication number
- MX2011012140A MX2011012140A MX2011012140A MX2011012140A MX2011012140A MX 2011012140 A MX2011012140 A MX 2011012140A MX 2011012140 A MX2011012140 A MX 2011012140A MX 2011012140 A MX2011012140 A MX 2011012140A MX 2011012140 A MX2011012140 A MX 2011012140A
- Authority
- MX
- Mexico
- Prior art keywords
- ranolazine
- cns disorders
- treatment
- migraine
- epilepsy
- Prior art date
Links
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000213 ranolazine Drugs 0.000 title abstract 2
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17817009P | 2009-05-14 | 2009-05-14 | |
| US27939509P | 2009-10-20 | 2009-10-20 | |
| PCT/US2010/034778 WO2010132696A1 (en) | 2009-05-14 | 2010-05-13 | Ranolazine for the treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011012140A true MX2011012140A (es) | 2012-02-28 |
Family
ID=42262042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012140A MX2011012140A (es) | 2009-05-14 | 2010-05-13 | Ranolazina para el tratamiento de problemas del snc. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100292217A1 (https=) |
| EP (1) | EP2429526A1 (https=) |
| JP (1) | JP2012526848A (https=) |
| AU (1) | AU2010248948A1 (https=) |
| CA (1) | CA2761771A1 (https=) |
| MX (1) | MX2011012140A (https=) |
| WO (1) | WO2010132696A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04011530A (es) * | 2002-05-21 | 2005-08-15 | Cv Therapeutics Inc | Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes. |
| US20080299195A1 (en) * | 2007-05-31 | 2008-12-04 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN113318111B (zh) * | 2021-06-21 | 2026-02-03 | 浙江大学 | Nav1.1激动剂在制备治疗自闭症的药物中的应用 |
| WO2025078664A1 (en) * | 2023-10-12 | 2025-04-17 | Celex Oncology Innovations Limited | Treatment of metastatic or invasive brain cancer |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| ATE142497T1 (de) * | 1989-06-23 | 1996-09-15 | Syntex Inc | Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| DE69429524T2 (de) * | 1993-09-24 | 2002-08-08 | The University Of British Columbia, Vancouver | Aminocyclohexylester und ihre anwendung |
| ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
| US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| US6541479B1 (en) * | 1997-12-02 | 2003-04-01 | Massachusetts College Of Pharmacy | Calcium channel blockers |
| US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| JP2004505886A (ja) * | 2000-02-18 | 2004-02-26 | スィーヴィー セラピューティクス インコーポレイテッド | 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤 |
| US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| ATE397938T1 (de) * | 2000-05-19 | 2008-07-15 | Amylin Pharmaceuticals Inc | Behandlung des akuten koronaren syndroms mit glp- 1 |
| WO2002007716A2 (en) * | 2000-07-21 | 2002-01-31 | Cv Therapeutics, Inc. | Method for treating angina |
| US6573264B1 (en) * | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| WO2003008411A1 (en) * | 2001-07-19 | 2003-01-30 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| US20080109040A1 (en) * | 2002-04-04 | 2008-05-08 | Luiz Belardinelli | Method of treating arrhythmias |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| MXPA04011530A (es) * | 2002-05-21 | 2005-08-15 | Cv Therapeutics Inc | Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes. |
| SG156681A1 (en) * | 2004-11-09 | 2009-11-26 | Cv Therapeutics Inc | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
| CA2593593A1 (en) * | 2005-01-06 | 2006-07-13 | Cv Therapeutics, Inc. | Sustained release pharmaceutical formulations comprising ranolazine |
| EP2117550A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of non-coronary microvascular diseases |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| US20090312340A1 (en) * | 2007-02-13 | 2009-12-17 | Whedy Wang | Use of ranolazine for the treatment of cardiovascular diseases |
| CA2678319A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
| EP2117509A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
| US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| US20080299195A1 (en) * | 2007-05-31 | 2008-12-04 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| CA2713521A1 (en) * | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| EP2337559A2 (en) * | 2008-09-04 | 2011-06-29 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
| WO2010068461A1 (en) * | 2008-11-25 | 2010-06-17 | Gilead Palo Alto, Inc. | Co-administration of ranolazine and cardiac glycosides |
-
2010
- 2010-05-13 JP JP2012511019A patent/JP2012526848A/ja active Pending
- 2010-05-13 WO PCT/US2010/034778 patent/WO2010132696A1/en not_active Ceased
- 2010-05-13 US US12/779,753 patent/US20100292217A1/en not_active Abandoned
- 2010-05-13 AU AU2010248948A patent/AU2010248948A1/en not_active Abandoned
- 2010-05-13 EP EP10720094A patent/EP2429526A1/en not_active Withdrawn
- 2010-05-13 MX MX2011012140A patent/MX2011012140A/es active IP Right Grant
- 2010-05-13 CA CA2761771A patent/CA2761771A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100292217A1 (en) | 2010-11-18 |
| CA2761771A1 (en) | 2010-11-18 |
| EP2429526A1 (en) | 2012-03-21 |
| JP2012526848A (ja) | 2012-11-01 |
| WO2010132696A1 (en) | 2010-11-18 |
| AU2010248948A1 (en) | 2011-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019011905A (es) | Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica. | |
| TN2013000362A1 (en) | Benzodioxane inhibitors of leukotriene production | |
| GB201103062D0 (en) | Method | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| MX2011012140A (es) | Ranolazina para el tratamiento de problemas del snc. | |
| IN2014DN09804A (https=) | ||
| MX364602B (es) | Inhibidores selectivos de glicosidasa y usos de los mismos. | |
| MY165728A (en) | Selective glycosidase inhibitors and uses thereof | |
| MY156274A (en) | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | |
| EP2485727A4 (en) | PYRROLOPYRAZOLE FOR THE TREATMENT OF CNS DISEASES | |
| MX2013007767A (es) | Producto de desulfuracion resistente a la aglomeracion. | |
| ZA201501262B (en) | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders | |
| MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
| UA108878C2 (ru) | Ингибиторы протеинтирозинкиназной активности | |
| PH12016500903A1 (en) | Novel methods for treating neurodegenerative diseases | |
| UA102515C2 (ru) | Новая лекарственная форма | |
| MX351631B (es) | Composiciones y metodos para reducir la incidencia de trastornos digestivos equinos. | |
| EP2616056A4 (en) | TERPENOID ANALOGUES AND USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL SUFFERING | |
| ZA201305970B (en) | Arylosulfonami for the treatment of cns diseases | |
| MX2010002032A (es) | Uso de flibanserina para el tratamiento de sintomas vasomotores. | |
| MX2009009361A (es) | Nueva forma de dosificacion. | |
| MX2012010443A (es) | Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos. | |
| WO2012174552A3 (en) | Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system | |
| EP3449917A3 (en) | Tapentadol for preventing chronification of pain | |
| MY174008A (en) | Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |